Ovid Therapeutics Inc. (1OT.F)

2,8400 +0,0200 (+0,71%) Alla chiusura: 08:05AM CEST

Ovid Therapeutics Inc.

41 Ninth Avenue
14th Floor
New York, NY 10001
United States
646 661 7661
https://www.ovidrx.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 40

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir	President, CEO & Chairman	956,21k	N/D	1953
Mr. Jeffrey A. Rona	Chief Business and Financial Officer	706,68k	N/D	1968
Mr. Thomas Michael Perone J.D., M.B.A.	General Counsel, Chief Compliance Officer & Corporate Secretary	692,27k	N/D	1965
Mr. Jason Tardio M.B.A.	Chief Operating Officer	606,05k	N/D	1977
Mr. Simon D. Kelner	Chief Human Resources Officer	N/D	N/D	1974
Dr. Dirk Haasner	Senior Vice President of Global Manufacturing & CMC QA	387,07k	N/D	1965
Dr. Todd F. Baumgartner M.D., M.P.H.	Senior Vice President of Regulatory Affairs	N/D	N/D	N/D
Dr. Julia Tsai Ph.D.	Senior Vice President of Clinical Development	N/D	N/D	1975
Ms. Meg Alexander	Chief Strategy Officer	N/D	N/D	N/D
Dr. Manoj Malhotra M.D.	Chief Medical Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Governance aziendale

L'ISS Governance QualityScore di Ovid Therapeutics Inc. al 1 maggio 2024 è 8. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 8; diritti degli azionisti: 7; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.